MultiCell (MCET) 10-Q 15 Oct 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Aug. 31, 2014	Oct. 08, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'MultiCell Technologies, Inc.	'
Entity Central Index Key	'0000811779	'
Current Fiscal Year End Date	'--11-30	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'MCET	'
Entity Common Stock, Shares Outstanding	'	4,329,363,052
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Aug-14	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Aug. 31, 2014	Nov. 30, 2013
Current assets	'	'
Cash and cash equivalents	$131,422	$146,205
Other current assets	12,230	32,600
Total current assets	143,652	178,805
Property and equipment, net of accumulated depreciation of $40,561	0	0
Other assets	280	280
Total assets	143,932	179,085
Current liabilities	'	'
Accounts payable and accrued expenses	1,175,698	1,072,521
Payable to related party	50,000	50,000
Advance from warrant holder	22,400	61,950
Convertible debentures	0	45,146
Current portion of deferred revenue	49,318	49,318
Total current liabilities	1,297,416	1,278,935
Non-current liabilities	'	'
Convertible debentures	37,676	0
Deferred revenue, net of current portion	412,435	449,424
Derivative liability related to Series B convertible preferred stock	33,063	18,147
Total non-current liabilities	483,174	467,571
Total liabilities	1,780,590	1,746,506
Commitments and contingencies	'	'
MultiCell Technologies, Inc. equity (deficiency)	'	'
Preferred stock	0	0
Common stock, $0.01 par value; 5,000,000,000 shares authorized; 4,207,140,830 and 2,610,793,503 shares issued and outstanding at August 31, 2014 and November 30, 2013, respectively	42,071,408	26,107,935
Additional paid-in capital	1,049,292	16,556,524
Accumulated deficit	-43,865,945	-43,489,211
Total MultiCell Technologies, Inc. stockholders' equity (deficiency)	-283,410	-362,917
Noncontrolling interests	-1,353,248	-1,204,504
Total equity (deficiency)	-1,636,658	-1,567,421
Total liabilities and equity (deficiency)	143,932	179,085
Series B Convertible Preferred Stock [Member]	'	'
MultiCell Technologies, Inc. equity (deficiency)	'	'
Preferred stock	461,835	461,835
Series I Convertible Preferred Stock [Member]	'	'
MultiCell Technologies, Inc. equity (deficiency)	'	'
Preferred stock	$0	$0

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Aug. 31, 2014	Nov. 30, 2013
Accumulated depreciation, property and equipment (in dollars)	$40,561	$40,561
Undesignated preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized/designated	963,000	963,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	4,207,140,830	2,610,793,503
Common stock, shares outstanding	4,207,140,830	2,610,793,503
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized/designated	17,000	17,000
Preferred stock, shares issued	3,448	3,448
Preferred stock, shares outstanding	3,448	3,448
Preferred stock, liquidation value (in dollars)	$470,316	$470,316
Series I Convertible Preferred Stock [Member]	'	'
Preferred stock, shares authorized/designated	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014	Aug. 31, 2013
Revenue	$12,329	$12,329	$36,988	$36,988
Operating expenses	'	'	'	'
Selling, general and administrative	197,341	207,753	619,500	626,092
Research and development	66,493	95,418	283,276	216,590
Stock-based compensation	-450,194	52,945	-385,097	175,866
Total operating expenses	-186,360	356,116	517,679	1,018,548
Income (loss) from operations	198,689	-343,787	-480,691	-981,560
Interest expense	-584	-707	-10,271	-2,058
Change in fair value of derivative liability	2,301	-902	-14,916	-11,342
Interest income	13	36	38	171
Total other income (expense)	1,730	-1,573	-25,149	-13,229
Net income (loss)	200,419	-345,360	-505,840	-994,789
Less net loss attributable to the noncontrolling interests	-24,610	-42,264	-129,106	-91,211
Net income (loss) attributable to MultiCell Technologies, Inc.	$225,029	($303,096)	($376,734)	($903,578)
Net income (loss) per common share:	'	'	'	'
Basic (in dollars per share)	$0	$0	$0	$0
Diluted (in dollars per share)	$0	$0	$0	$0
Weighted-average common shares outstanding:	'	'	'	'
Basic (in shares)	3,971,690,410	2,105,332,608	3,519,485,044	1,730,465,999
Diluted (in shares)	5,072,336,768	2,105,332,608	3,519,485,044	1,730,465,999

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Series B Convertible Preferred Stock [Member]
						Preferred Stock [Member]
Balance at Nov. 30, 2012	($1,618,462)	$13,498,030	$27,755,595	($42,254,594)	($1,079,328)	$461,835
Balance (in shares) at Nov. 30, 2012	'	1,349,803,029	'	'	'	3,448
Issuance of common stock for conversion of 4.75% debentures	9,430	10,404,936	-10,395,506	0	0	0
Issuance of common stock for conversion of 4.75% debentures (in shares)	'	1,040,493,584	'	'	'	'
Issuance of common stock for exercise of warrants	1,027,870	9,430	1,018,440	0	0	0
Issuance of common stock for exercise of warrants (in shares)	'	943,000	'	'	'	'
Stock-based compensation	175,866	0	175,866	0	0	0
Net loss	-994,789	0	0	-903,578	-91,211	0
Balance at Aug. 31, 2013	-1,400,085	23,912,396	18,554,395	-43,158,172	-1,170,539	461,835
Balance (in shares) at Aug. 31, 2013	'	2,391,239,613	'	'	'	3,448
Balance at Nov. 30, 2013	-1,567,421	26,107,935	16,556,524	-43,489,211	-1,204,504	461,835
Balance (in shares) at Nov. 30, 2013	'	2,610,793,503	'	'	'	3,448
Issuance of common stock for conversion of 4.75% debentures	7,470	15,956,003	-15,948,533	0	0	0
Issuance of common stock for conversion of 4.75% debentures (in shares)	'	1,595,600,327	'	'	'	'
Issuance of common stock for exercise of warrants	814,230	7,470	806,760	0	0	0
Issuance of common stock for exercise of warrants (in shares)	'	747,000	'	'	'	'
Stock-based compensation	-385,097	0	-365,459	0	-19,638	0
Net loss	-505,840	0	0	-376,734	-129,106	0
Balance at Aug. 31, 2014	($1,636,658)	$42,071,408	$1,049,292	($43,865,945)	($1,353,248)	$461,835
Balance (in shares) at Aug. 31, 2014	'	4,207,140,830	'	'	'	3,448

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical)	9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Debt Conversion, Original Debt, Interest Rate of Debt	4.75%	4.75%

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Cash flows from operating activities	'	'
Net loss	($505,840)	($994,789)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Stock-based compensation	-385,097	175,866
Change in fair value of derivative liability	14,916	11,342
Changes in assets and liabilities	'	'
Other current assets	20,370	-3,324
Accounts payable and accrued liabilities	103,176	-20,528
Deferred revenue	-36,988	-36,988
Net cash used in operating activities	-789,463	-868,421
Cash flows from investing activities	0	0
Cash flows from financing activities	'	'
Proceeds from the exercise of stock warrants	814,230	1,027,870
Change in advance from warrant holder	-39,550	-180,800
Net cash provided by financing activities	774,680	847,070
Net decrease in cash and cash equivalents	-14,783	-21,351
Cash and cash equivalents at beginning of period	146,205	199,472
Cash and cash equivalents at end of period	131,422	178,121
Supplemental Disclosures of Cash Flow Information:	'	'
Cash paid for interest	1,486	2,142
Noncash Investing and Financing Activities:	'	'
Issuance of common stock for conversion of 4.75% debentures	$7,470	$9,430

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Debt Conversion, Original Debt, Interest Rate of Debt	4.75%	4.75%

ORGANIZATION_AND_NATURE_OF_OPE

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Aug. 31, 2014
Accounting Policies [Abstract]	'
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	'
	NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS
	ORGANIZATION AND NATURE OF OPERATIONS
	MultiCell Technologies, Inc. (“MultiCell”), has two subsidiaries, Xenogenics Corporation (“Xenogenics”) and MultiCell Immunotherapeutics, Inc. (“MCTI”). MultiCell holds 95.3% of the outstanding shares (on an as-if-converted to common stock basis) of Xenogenics. Prior to August 15, 2014, MultiCell held approximately 67% of the outstanding shares (on an as-if-converted to common stock basis) of MCTI. Commencing on August 15, 2014, MultiCell’s ownership of MCTI was increased to 85.1% of the outstanding shares (on an as-if-converted to common stock basis) as a result of the conversion of $1,165,867 of inter-company liabilities into shares of common stock of MCTI.  As used herein, the “Company” refers to MultiCell, together with Xenogenics and MCTI.
	The Company’s therapeutic development platform includes several patented techniques used to: (i) isolate, characterize and differentiate stem cells from human liver; (ii) control the immune response at transcriptional and translational levels through double-stranded RNA (“dsRNA”)-sensing molecules such as the Toll-like Receptors (“TLRs”), RIG-I-like receptor (“RLR”), and Melanoma Differentiation-Associated protein 5 (“MDA-5”) signaling; (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; and (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway. The Company’s medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent™, for interventional cardiology and peripheral vessel applications.
	BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements and related notes of MultiCell and its subsidiaries have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial statements. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for a fair presentation have been included. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2013, previously filed with the SEC. The results of operations for the three-month and nine-month periods ended August 31, 2014, are not necessarily indicative of the operating results for the fiscal year ending November 30, 2014. The condensed consolidated balance sheet as of November 30, 2013, has been derived from the Company’s audited consolidated financial statements.
	RECENT ACCOUNTING PRONOUNCEMENTS
	In August 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU 2014-15, Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern, (“ASU 2014-15”). ASU 2014-15 requires management to perform interim and annual assessments on whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year of the date the financial statements are issued and to provide related disclosures, if required. ASU 2014-15 will be effective for the Company’s fiscal year beginning December 1, 2016 and subsequent interim periods. Management is currently evaluating the impact of the pending adoption of ASU 2014-15 on the Company’s consolidated financial statements.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 will be effective for the Company retrospectively beginning December 1, 2017, with early adoption not permitted. Management is currently evaluating the impact of the pending adoption of ASU 2014-09 on the Company’s consolidated financial statements.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”) to provide guidance on the presentation of unrecognized tax benefits. ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. ASU 2013-11 is effective January 1, 2015, with earlier adoption permitted. ASU 2013-11 should be applied prospectively with retroactive application permitted. Management is currently evaluating the impact of the pending adoption of ASU 2013-11 on the Company’s consolidated financial statements.

GOING_CONCERN

GOING CONCERN	9 Months Ended
	Aug. 31, 2014
Going Concern [Abstract]	'
Going Concern [Text Block]	'
	NOTE 2. GOING CONCERN
	These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of August 31, 2014, the Company has operating and liquidity concerns and, as a result of recurring losses, has incurred an accumulated deficit of $43,865,945. The Company will have to raise additional capital in order to initiate Phase IIb/III clinical trials for MCT-125, its therapeutic product for the treatment of fatigue in multiple sclerosis patients, conduct further research on MCT-465 and MCT-485, its therapeutic products for the treatment of primary liver cancer, and initiate clinical trials for Xenogenic’s bioabsorbable, drug eluting stent, the Ideal BioStent™. The Company’s management is evaluating several sources of financing for the Company’s clinical trial program. Additionally, with its strategic shift in focus to therapeutic programs and technologies, management expects the Company’s future cash requirements to increase significantly as it advances the Company’s therapeutic programs into clinical trials. Until the Company is successful in raising additional funds, it may have to prioritize its therapeutic programs and delays may be necessary in some of the Company’s development programs.
	Since March 2008, the Company has operated on working capital provided by La Jolla Cove Investors, Inc. (“LJCI”). As further described in Note 4 to these condensed consolidated financial statements, under the terms of the LJCI Agreement (as defined below), LJCI can convert a portion of the Debenture (as defined below) by simultaneously exercising the LJCI Warrant (as defined below) at $1.09 per share. As of August 31, 2014, there were 3,767,629 shares remaining on the LJCI Warrant and a balance of $37,676 remaining on the Debenture. Should LJCI continue to exercise all of its remaining warrants, approximately $4.1 million of cash would be provided to the Company. The LJCI Agreement limits LJCI’s investment to an aggregate ownership that does not exceed 9.99% of the common stock of MultiCell. The Company expects that LJCI will continue to exercise the warrants and convert the Debenture through February 28, 2016, the date that the Debenture is due and the LJCI Warrant expires, subject to the limitations of the LJCI Agreement and the availability of authorized common stock of MultiCell.
	These factors, among others, create an uncertainty about the Company’s ability to continue as a going concern. There can be no assurance that LJCI will continue to exercise its warrant to purchase MultiCell’s common stock, or that the Company will be able to successfully acquire the necessary capital to continue its on-going research efforts and bring its products to the commercial market. Management’s plans to acquire future funding include the potential sale of shares of the Company’s common and/or preferred stock, the sale of warrants, and continued sales of the Company’s proprietary media, immortalized cells and primary cells to the pharmaceutical industry. Additionally, the Company continues to pursue research projects, government grants and capital investment. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

PAYABLE_TO_RELATED_PARTY

PAYABLE TO RELATED PARTY	9 Months Ended
	Aug. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 3. – PAYABLE TO RELATED PARTY
	In connection with an acquisition in September 2005, the Company assumed certain liabilities in the amount of $200,000, payable to an individual who is a current director of the Company. The liability is to be paid to this individual over time as determined by the remainder of the members of the board of directors. The balance of the liability owed to this director is $50,000 as of August 31, 2014 and November 30, 2013.

CONVERTIBLE_DEBENTURES

CONVERTIBLE DEBENTURES	9 Months Ended
	Aug. 31, 2014
Debt Disclosure [Abstract]	'
Long-term Debt [Text Block]	'
	NOTE 4. CONVERTIBLE DEBENTURES
	MultiCell entered into a Securities Purchase Agreement with LJCI on February 28, 2007 (“the LJCI Agreement”) pursuant to which MultiCell agreed to sell a convertible debenture in the principal amount of $100,000 and originally scheduled to mature on February 28, 2012 (the “Debenture”). On August 16, 2011, MultiCell and LJCI amended the Debenture to extend the maturity date to February 28, 2014. On February 20, 2014, MultiCell and LJCI amended the Debenture to further extend the maturity date to February 28, 2016. The Debenture accrues interest at 4.75% per year, payable in cash or shares of MultiCell’s common stock at the option of LJCI. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of its common stock (the “LJCI Warrant”) at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. On August 16, 2011, MultiCell and LJCI amended the LJCI Warrant to extend the expiration date to February 28, 2014. On February 20, 2014, MultiCell and LJCI amended the LJCI Warrant to further extend the expiration date to February 28, 2016. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share. The LJCI Agreement limits LJCI’s investment to an aggregate common stock ownership that does not exceed 9.99% of the outstanding shares of common stock of MultiCell.
	The Debenture is convertible at the option of LJCI at any time up to maturity into the number of shares of MultiCell’s common stock determined by the dollar amount of the Debenture being converted multiplied by 110, minus the product of the Conversion Price (as defined below) multiplied by 100 times the dollar amount of the Debenture being converted, with the entire result divided by the Conversion Price. The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert. LJCI converted $7,470 and $9,430 of the Debenture into 1,595,600,327 and 1,040,493,584 shares, respectively, of the Company’s common stock during the nine months ended August 31, 2014 and 2013, respectively. Simultaneously with these conversions, LJCI exercised warrants to purchase 747,000 shares and 943,000 shares of the Company’s common stock during the nine months ended August 31, 2014 and 2013, respectively. Proceeds from the exercise of the warrants were $814,230 and $1,027,870 for the nine months ended August 31, 2014 and 2013, respectively. At times, LJCI makes advances to the Company prior to the exercise of warrants. At August 31, 2014 and November 30, 2013, LJCI had advanced $22,400 and $61,950, respectively, to the Company in advance of LJCI’s exercise of warrants.
	As of August 31, 2014, the remainder of the Debenture in the amount of $37,676 could have been converted by LJCI into approximately 8.6 billion shares of the Company’s common stock, which would require LJCI to simultaneously exercise and purchase all of the remaining 3,767,629 shares of the Company’s common stock under the LJCI Warrant at $1.09 per share. As of November 30, 2013, the balance of the Debenture was $45,146. For the Debenture, upon receipt of a conversion notice from the holder, MultiCell may elect to immediately redeem that portion of the Debenture that the holder elected to convert in such conversion notice, plus accrued and unpaid interest. MultiCell, at its sole discretion, has the right, without limitation or penalty, to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

LICENSE_AGREEMENTS_AND_DEFERRE

LICENSE AGREEMENTS AND DEFERRED REVENUE	9 Months Ended
	Aug. 31, 2014
Deferred Revenue [Abstract]	'
Deferred Revenue [Text Block]	'
	NOTE 5. LICENSE AGREEMENTS AND DEFERRED REVENUE
	Corning Incorporated
	The Company has an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell the Company’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (“ADME/Tox assays”). The Company retained and will continue to support all of its existing licensees. The Company retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. The Company also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to produce therapeutic proteins using the Company’s BioFactories™ technology, to identify drug targets and for other applications related to the Company’s internal drug development programs. In consideration for the license granted, Corning paid the Company $375,000 upon execution of the Agreement, and an additional $375,000 upon the completion of a transition period. In addition, Corning purchased inventory and equipment from the Company and reimbursed the Company for laboratory costs and other expenses during a transition period. The Company is recognizing the income ratably over a 17-year period. The Company recognized $11,029 and $33,088, respectively, in income for each of the three months and nine months ended August 31, 2014 and 2013. The balance of deferred revenue from this license was $444,853 and $477,942 at August 31, 2014 and November 30, 2013, respectively, and will be amortized into revenue through October 2024.
	Pfizer Inc.
	The Company has another license agreement with Pfizer Inc. (“Pfizer”), for which revenue is being deferred. The Company recognized $1,300 and $3,900, respectively, in income for each of the three months and nine months ended August 31, 2014 and 2013. The balance of deferred revenue from this license was $16,900 and $20,800 at August 31, 2014 and November 30, 2013, respectively, and will be amortized into revenue through January 2018.
	The Foreclosure Sale Agreement and the Rutgers License Agreement
	On September 30, 2010, Xenogenics entered into a Foreclosure Sale Agreement (the “Foreclosure Sale Agreement”) with Venture Lending & Leasing IV, Inc., Venture Lending & Leasing V, Inc. and Silicon Valley Bank (collectively, the “Sellers”). Pursuant to the Foreclosure Sale Agreement, as amended on September 30, 2011, on October 23, 2012, and on October 11, 2013, Xenogenics acquired all of the Sellers’ interests in certain bioabsorbable stent assets (known as “Ideal BioStent™”) and related technologies.
	To supplement the technology acquired under the Foreclosure Sale Agreement, Xenogenics also entered in to a license agreement (the “Rutgers License Agreement”) with Rutgers, The State University of New Jersey (“Rutgers”) effective September 30, 2010. The term of the Rutgers License Agreement commenced on September 30, 2010, and was to terminate on the earlier of (i) the expiration of all valid patents granted with respect to the licensed technology (or products commercialized therefrom) in a country, and (ii) ten years from the date of first commercial sale in a country.
	Pursuant to the Rutgers License Agreement, Rutgers granted Xenogenics a worldwide exclusive license to exploit and commercialize certain patents and other intellectual property rights, as further described in the Rutgers License Agreement, relating to bioabsorbable stents for interventional cardiology and peripheral vascular applications. In consideration for the license and other rights granted under the Rutgers License Agreement, Xenogenics paid Rutgers a license fee of $50,000. In addition, under the Rutgers License Agreement, Xenogenics was obligated to pay Rutgers a license maintenance fee of $25,000 on the third anniversary of the Rutgers License Agreement, and $50,000 on the fourth anniversary. Additionally, Xenogenics agreed to pay Rutgers for unpaid costs of $136,000 incurred by Rutgers prior to the effective date of the Rutgers License Agreement for preparing, filing, prosecuting, defending, and maintaining all United States patent applications and patents covered under the Rutgers License Agreement. Additionally, Xenogenics was also required to make additional cash payments to Rutgers upon the achievement of certain milestones. None of these milestones were ever achieved, and accordingly, none of these obligations were ever accrued. Furthermore, upon the sale of products commercialized using the technology licensed pursuant to the Rutgers License Agreement, Xenogenics was required to make royalty payments to Rutgers in an amount equal to three percent of the annual aggregate gross amounts charged for such products less deductions for expenses such as sales/use taxes, transportation charges and trade discounts. No sales were ever made that required the payment of any royalty.
	It became apparent during the evaluation and development of the Ideal BioStent™ that the use of intellectual property licensed from Rutgers would have introduced complications in the design of the Ideal BioStent. As a result, Xenogenics abandoned the use of the Rutgers technology effective January 2014. On January 31, 2014, Rutgers notified Xenogenics of its alleged default of the provisions in the Rutgers License Agreement. On May 9, 2014, Rutgers issued a notice of termination of the Rutgers License Agreement, and demanded payment of unpaid license fees of $25,000, unpaid patent costs of $75,665, and accrued interest of $8,375. All of these claimed fees, costs, and interest have been accrued in the accompanying condensed consolidated financial statements. Management is currently evaluating the merits of these claims.

SERIES_B_CONVERTIBLE_PREFERRED

SERIES B CONVERTIBLE PREFERRED STOCK (Series B Convertible Preferred Stock [Member])	9 Months Ended
	Aug. 31, 2014
Series B Convertible Preferred Stock [Member]	'
Equity [Abstract]	'
Preferred Stock [Text Block]	'
	NOTE 6. SERIES B CONVERTIBLE PREFERRED STOCK
	The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated 17,000 shares as Series B convertible preferred stock. The Series B convertible preferred stock does not have voting rights.
	The Series B shares are convertible at any time into shares of the Company common stock at a conversion price determined by dividing the purchase price per share of $100 by the conversion price. The conversion price was originally $0.32 per share. Upon the occurrence of an event of default (as defined in the applicable Series B convertible preferred stock purchase agreement), the conversion price of the Series B shares shall be reduced to 85% of the then-applicable conversion price of such shares. The conversion price is subject to equitable adjustment in the event of any stock splits, stock dividends, recapitalizations and the like. In addition, the conversion price is subject to weighted average anti-dilution adjustments in the event the Company sells common stock or other securities convertible into or exercisable for common stock at a per share price, exercise price or conversion price lower than the conversion price then in effect in any transaction (other than in connection with an acquisition of the securities, assets or business of another company, a joint venture and/or the issuance of employee stock options). As a result of the Company issuing shares of its common stock upon conversion of convertible debentures and upon the exercise of warrants both at prices lower than the conversion price of the Series B convertible preferred stock, and due to the Company not paying the Series B dividends on a monthly basis (as discussed below), the conversion price of the Series B convertible preferred stock has been reduced to $0.0073 per share as of August 31, 2014 and to $0.0114 per share as of November 30, 2013. Pursuant to the applicable Series B convertible preferred stock purchase agreement, each investor may only convert that number of shares of Series B convertible preferred stock into that number of shares of the Company’s common stock that does not exceed 9.99% of the outstanding shares of common stock of the Company on the date of conversion.
	Commencing on the date of issuance of the Series B convertible preferred stock until the date a registration statement registering the shares of the Company’s common stock underlying the preferred stock and warrants issued is declared effective by the SEC, the Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum. The dividend was payable monthly in arrears in cash on the last day of each month based on the number of shares of Series B convertible preferred stock outstanding as of the first day of that month. In the event the Company did not pay the Series B convertible preferred dividends when due, the conversion price of the Series B preferred shares was reduced to 85% of the otherwise applicable conversion price. The Company did not pay the required monthly Series B preferred dividends beginning on November 30, 2006, which, in part, caused the conversion price to be reduced. Subsequent to November 30, 2010, the Company received an opinion of outside counsel providing for the removal of the restrictive legend on the Series B convertible preferred stock, which in turn terminated the requirement to accrue the related dividends. Accordingly, no dividends have been accrued since November 30, 2010. Total accrued but unpaid preferred dividends recorded in the accompanying condensed consolidated balance sheet as of August 31, 2014 and November 30, 2013 are $290,724, of which $125,516 are recorded in permanent equity with the Series B convertible preferred stock and $165,208 are recorded as a current liability in accounts payable and accrued expenses.
	The conversion feature which gives the holders of the Series B convertible preferred stock the right to acquire shares of the Company’s common stock is an embedded derivative. As of August 31, 2014 and November 30, 2013, there were 3,448 shares of Series B convertible preferred stock that were convertible into 47,232,877 and 30,245,614 shares of common stock of the Company, respectively. The fair value of the conversion feature was estimated at $33,063 ($0.0007 per share of common stock) and $18,147 ($0.0006 per share of common stock) at August 31, 2014 and November 30, 2013, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:
		August 31,			May 31,			February 28,			November 30,
		2014			2014			2014			2013
	Fair value of common stock	$	0.0007		$	0.0008		$	0.0008		$	0.0007
	Conversion price of preferred stock	$	0.0073		$	0.0078		$	0.0095		$	0.0114
	Risk free interest rate		2.35	%		2.48	%		2.66	%		2.75	%
	Expected life		10 Years			10 Years			10 Years			10 Years
	Dividend yield		-			-			-			-
	Volatility		143	%		144	%		142	%		142	%
	Pursuant to the Certificate of Designation of the Series B convertible preferred stock, in the event of any dissolution or winding up of the Company, whether voluntary or involuntary, holders of each outstanding share of Series B convertible preferred stock shall be entitled to be paid second in priority to the Series I preferred stockholders out of the assets of the Company available for distribution to stockholders, an amount equal to $100 per share of Series B convertible preferred stock held plus any declared but unpaid dividends. However, as discussed below, no shares of the Company’s Series I convertible preferred stock were outstanding at August 31, 2014. After such payment has been made in full, such holders of Series B convertible preferred stock shall be entitled to no further participation in the distribution of the assets of the Company.

SERIES_I_CONVERTIBLE_PREFERRED

SERIES I CONVERTIBLE PREFERRED STOCK (Series I Convertible Preferred Stock [Member])	9 Months Ended
	Aug. 31, 2014
Series I Convertible Preferred Stock [Member]	'
Equity [Abstract]	'
Preferred Stock [Text Block]	'
	NOTE 7. SERIES I CONVERTIBLE PREFERRED STOCK
	The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated 20,000 shares as Series I convertible preferred stock. On July 13, 2004, the Company completed a private placement of Series I convertible preferred stock and a total of 20,000 shares were originally sold to accredited investors. As of August 31, 2014 and November 30, 2013, all of the shares of Series I convertible preferred stock had been converted into shares of the common stock of the Company and no shares of the Company’s Series I convertible preferred stock were outstanding.

STOCK_COMPENSATION_PLANS

STOCK COMPENSATION PLANS	9 Months Ended
	Aug. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	NOTE 8. STOCK COMPENSATION PLANS
	On July 11, 2011, at the Company’s Annual Meeting of Stockholders, the stockholders approved an amendment to increase the number of shares reserved under the 2004 Equity Incentive Plan (the “2004 Plan”) to a total of 70,974,213 shares. Additionally, an annual increase in the number of shares reserved under the 2004 Plan was approved and certain prior increases in the number of shares reserved for issuance under the 2004 Plan were ratified. Furthermore, on each of December 1, 2011 and on December 1, 2012, the number of shares reserved under the 2004 Plan was increased by an additional 1,500,000 shares pursuant to the provisions of the 2004 Plan. The purpose of the 2004 Plan was to provide a means by which eligible recipients of stock awards could be given the opportunity to benefit from increases in the value of the Company’s common stock through granting of incentive stock options (“ISO”), non-statutory stock options, stock purchase awards, stock bonus awards, stock appreciation rights, stock unit awards and other stock awards. Under the provisions of the 2004 Plan, the 2004 Plan terminated on March 2, 2014, and as such, there are no additional shares of common stock available for future awards under the 2004 Plan.
	Generally accepted accounting principles for stock options require the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements, which is measured based on the grant date fair value of the award, and require the stock option compensation expense to be recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period), net of estimated forfeitures. The estimation of forfeitures requires significant judgment, and to the extent actual results or updated estimates differ from the current estimates, such resulting adjustment will be recorded in the period estimates are revised. No income tax benefit has been recognized for stock-based compensation arrangements and no compensation cost has been capitalized in the consolidated balance sheets.
	A summary of the status of stock options granted by MultiCell at August 31, 2014, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining		Aggregate
		Under		Exercise		Contractual		Intrinsic
		Option		Price		Life		Value
	Outstanding at November 30, 2013		50,399,503	$	0.004		3.7 years	$	-
	Granted		25,074,710		0.0008
	Exercised		-		-
	Expired or forfeited		-4,030,000		0.011
	Outstanding at August 31, 2014		71,444,213	$	0.0025		3.6 years	$	-
	Exercisable at August 31, 2014		54,300,697	$	0.003		3.4 years	$	-
	On January 15, 2014, the MultiCell Board of Directors granted an option to each of the five members of the Board of Directors to purchase 4,600,000 shares of MultiCell’s common stock at $0.0008 per share. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 2,074,710 shares of MultiCell’s common stock at $0.0008 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant. On August 16, 2013, the MultiCell Board of Directors granted an option to each of the five members of the Board of Directors to purchase 5,000,000 shares of MultiCell’s common stock at $0.0011 per share. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 5,000,000 shares of MultiCell’s common stock at $0.0011 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant.
	The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option pricing model. The weighted-average fair value of stock options granted during the nine months ended August 31, 2014 was $0.0007 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2014 were risk-free interest rate of 1.68%, volatility of 140%, expected life of 5.0 years, and dividend yield of zero. The weighted-average fair value of stock options granted during the nine months ended August 31, 2013 was $0.0011 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2013 were risk-free interest rate of 1.60%, volatility of 175%, expected life of 5.0 years, and dividend yield of zero. The assumptions employed in the Black-Scholes option pricing model include the following: (i) the expected life of stock options represents the period of time that the stock options granted are expected to be outstanding prior to exercise; (ii) the expected volatility is based on the historical price volatility of the Company’s common stock; (iii) the risk-free interest rate represents the U.S. Treasury Department’s constant maturities rate for the expected life of the related stock options; and (iv) the dividend yield represents anticipated cash dividends to be paid over the expected life of the stock options.
	For the three months ended August 31, 2014 and 2013, MultiCell reported stock-based compensation expense for services related to stock options of $10,806 and $1,893, respectively. For the nine months ended August 31, 2014 and 2013, MultiCell reported stock-based compensation expense for services related to stock options of $32,741 and $10,705, respectively. As of August 31, 2014, there was approximately $12,000 of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately 1.2 years. The intrinsic values at August 31, 2014 are based on a closing price of $0.0007.
	In October 2010, Xenogenics adopted the 2010 Stock Incentive Plan (the “2010 Plan”) which authorized the granting of stock awards to Xenogenics’ employees, directors, and consultants. As originally adopted, the 2010 Plan provided that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 5,000,000 shares of common stock. On February 3, 2011, the 2010 Plan was amended such that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 8,000,000 shares of common stock. The purpose of the 2010 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of Xenogenics’ common stock through granting of ISOs, non-statutory stock options, stock bonus awards, stock appreciation rights, and rights to acquire restricted stock. ISOs may be granted only to employees. The exercise price of each ISO granted under the 2010 Plan must equal 100% of the market price of Xenogenics’ stock on the date of the grant. A 10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant. The Board of Directors of Xenogenics, in its discretion, shall determine the exercise price of each nonstatutory stock option. An option’s maximum term is 10 years.
	A summary of the status of Xenogenics’ stock options at August 31, 2014, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining
		Under		Exercise		Contractual
		Option		Price		Life
	Outstanding at November 30, 2013		4,250,000	$	0.246		2.3 years
	Granted		-	$	-
	Exercised		-	$	-
	Expired or forfeited		-3,000,000	$	0.246
	Outstanding at August 31, 2014		1,250,000	$	0.246		2.4 years
	Exercisable at August 31, 2014		1,250,000	$	0.246		2.4 years
	In November 2010, Xenogenics granted an option to a prospective executive officer to purchase an aggregate of 2,500,000 shares of its common stock, exercisable at $0.246 per share of common stock and having an expiration date in November 2015. The option to acquire 500,000 of the shares vested on the grant date and the remaining 2,000,000 option shares were to vest in the future upon the achievement of specified milestones. The fair value of these options was estimated to be $576,250, or $0.2305 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 1.23%, volatility of 165%, expected life of five years, and dividend yield of zero. This prospective executive officer resigned in May 2014 and the rights under this option were forfeited in August 2014. At the date of the forfeiture, only the initial option to acquire 500,000 shares had vested, and the remaining 2,000,000 option shares remained unvested because the specified milestones had not been achieved. The share-based compensation related to these 2,000,000 option shares ($461,000) had been recognized over the periods of time, originally estimated on the date of grant, that management expected each of the specified milestones was likely to be achieved. As of the date of forfeiture, all of the share-based compensation related to these performance-based options had been recognized in the condensed consolidated financial statements. Under GAAP, if vesting is based solely on one or more performance or service conditions, any previously recognized compensation cost is reversed if the award does not vest (that is, the requisite service is not rendered). Accordingly, Xenogenics reversed the compensation cost for these options in the amount of $461,000 during the three months ended August 31, 2014 when the options were forfeited. For the nine months ended August 31 2014, Xenogenics reported a net reversal of stock-based compensation in the amount $417,838, representing stock-based compensation of $43,162 less the reversal of $461,000.
	For the three months and the nine months ended August 31 2013, Xenogenics reported stock-based compensation of $51,052 and $165,161, respectively. As of August 31, 2014, there was no unrecognized compensation cost related to stock-based payments to be recognized in the future for option grants through August 31, 2014.

STOCK_WARRANTS

STOCK WARRANTS	9 Months Ended
	Aug. 31, 2014
Warrants and Rights Note Disclosure [Abstract]	'
Warrants Disclosure [Text Block]	'
	NOTE 9. STOCK WARRANTS
	Since the Company’s inception, it has financed its operations primarily through the issuance of debt or equity instruments, which have often included the issuance of warrants to purchase shares of the Company’s common stock.
	As further described in Note 4 to these condensed consolidated financial statements, MultiCell entered into the LJCI Agreement pursuant to which MultiCell agreed to sell the Debenture in the principal amount of $100,000. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of MultiCell’s common stock at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share. As further described to Note 4 to these condensed consolidated financial statements, on February 20, 2014, MultiCell and LJCI amended the LJCI Warrant to extend the expiration date of the warrants to February 28, 2016. During the nine months ended August 31, 2014, LJCI exercised warrants to purchase 747,000 shares of MultiCell’s common stock, resulting in proceeds to the Company of $814,230. During the nine months ended August 31, 2013, LJCI exercised warrants to purchase 943,000 shares of MultiCell’s common stock, resulting in proceeds to the Company of $1,027,870.
	A summary of the status of warrants at August 31, 2014, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining	Aggregate
		Under		Exercise		Contractual	Intrinsic
		Warrants		Price		Life	Value
	Outstanding at November 30, 2013		7,829,030	$	0.72	1.5 years	$	-
	Issued		-	$	-
	Exercised		-747,000	$	1.09
	Expired		-134,000	$	0.5
	Outstanding at August 31, 2014		6,948,030	$	0.68	2.0 years	$	-

NET_INCOME_LOSS_PER_COMMON_SHA

NET INCOME (LOSS) PER COMMON SHARE	9 Months Ended
	Aug. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	NOTE 10. NET INCOME (LOSS) PER COMMON SHARE
	Basic net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted-average number of shares of outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock and potentially dilutive common stock outstanding during the period. The dilutive effect of outstanding options and warrants is reflected in diluted net income (loss) per common share by application of the treasury stock method. The dilutive effect of the conversion of the Series B convertible preferred stock and the convertible debentures is reflected in diluted net income (loss) per common share by application of the as-if converted method. The calculation of diluted net income (loss) per common share excludes all anti-dilutive common shares. The following table sets forth the computation of basic and diluted income (loss) per common share for the periods indicated:
		For the Three Months Ended				For the Nine Months Ended
		August 31,				August 31,
		2014		2013		2014			2013
	Numerator:
	Net income (loss)	$	225,029	$	-303,096	$	-376,734		$	-903,578
	Interest on convertible debentures		451		-		-			-
	Numerator for diluted income (loss) per common share	$	225,480	$	-303,096	$	-376,734		$	-903,578
	Denominator:
	Weighted-average shares of common stock - basic		3,971,690,410		2,105,332,608		3,519,485,044			1,730,465,999
	Dilutive effect of:
	Conversion of Series B converible preferred stock		44,205,128		-		-			-
	Conversion of convertible debentures and exercise of LJCI warrants		1,056,441,230		-		-			-
	Weighted-average shares of common stock - diluted		5,072,336,768		2,105,332,608		3,519,485,044			1,730,465,999
	Net income (loss) per common share - basic	$	0	$	0	$	0		$	0
	Net income (loss) per common share - diluted	$	0	$	0	$	0		$	0
	Common stock equivalents excluded from income (loss) per common share calculations because their effect would have been anti-dilutive are as follows:
		For the Three Months Ended				For the Nine Months Ended
		August 31,				August 31,
		2014		2013		2014		2013
	Warrants		3,180,401		7,974,030	6,948,030			7,974,030
	Stock options		71,444,213		50,399,503	71,444,213			50,399,503
	Series B convertible preferred stock		-		27,806,452	47,232,877			27,806,452
	Convertible debenture		-		5,819,876,621	8,630,382,163			5,819,876,621
			74,624,614		5,906,056,606	8,756,007,283			5,906,056,606
	MultiCell does not currently have sufficient authorized shares of its common stock to meet the commitments entered into under the Debenture and the related LJCI Warrants. As further discussed in Note 4 to the condensed consolidated financial statements, upon the conversion of any portion of the remaining $37,676 principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the remaining 3,767,629 warrant shares equal to the percentage of the dollar amount of the Debenture being converted. The LJCI Agreement limits LJCI’s investment to an aggregate common stock ownership that does not exceed 9.99% of the outstanding shares of common stock of MultiCell. Furthermore, MultiCell has the right to redeem that portion of the Debenture that the holder may elect to convert and also has the right to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS

9 Months Ended

Aug. 31, 2014

Fair Value Disclosures [Abstract]

'

Fair Value Disclosures [Text Block]

'

NOTE 11. FAIR VALUE MEASUREMENTS

For assets and liabilities measured at fair value, the Company uses the following hierarchy of inputs:

·

Level one — Quoted market prices in active markets for identical assets or liabilities;

·

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

·

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the Company and reflect those assumptions that a market participant would use.

Liabilities measured at fair value on a recurring basis at August 31, 2014 and November 30, 2013, are summarized as follows:

August 31, 2014

November 30, 2013

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total

Derivative liability

$

-

$

33,063

$

-

$

33,063

$

-

$

18,147

$

-

$

18,147

As further described in Note 6, the fair value of the derivative liability is determined using the Black-Scholes pricing model.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Aug. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 12. SUBSEQUENT EVENTS
	Stock Issued for Conversion of Debenture and Exercise of Warrants
	As more fully discussed in Note 4 to these condensed consolidated financial statements, MultiCell sold the Debenture to LJCI and issued LJCI a stock warrant in connection with the Debenture. During the period subsequent to August 31, 2014 through the date of issuance of the condensed consolidated financial statements, LJCI converted $500 of the Debenture into 122,172,222 shares of MultiCell’s common stock. Simultaneously with the conversions of the Debenture, LJCI was required to exercise warrants to purchase 50,000 shares of MultiCell’s common stock at $1.09 per share. The total proceeds from the exercise of the warrants were $54,500.
	The Foreclosure Sale Agreement
	As further described in Note 5 to these condensed consolidated financial statements, on October 11, 2013, Xenogenics entered into Amendment No. 3 to the Foreclosure Sale Agreement which further extended the deadlines for the achievement of the milestones under the Foreclosure Sale Agreement by an additional 12 months. Xenogenics is required to use Good Faith Reasonable Efforts (as defined in the Foreclosure Sale Agreement) to achieve these milestones. Failure to achieve any of these milestones shall result in all milestone payments, totaling $4.3 million, becoming immediately due and payable, unless Xenogenics’ failure to use Good Faith Reasonable Efforts is due to Technical Difficulties (as defined in the Foreclosure Sale Agreement) or to Financial Hardship (as defined in the Foreclosure Sale Agreement), in which case Xenogenics can elect to (1) pay all remaining milestone payments or (2) assign the Ideal BioStent™ technologies back to the Sellers. The earliest of the milestone extensions under Amendment No. 3 to the Foreclosure Sale Agreement expired on September 30, 2014. Xenogenics has asked for and expects that an Amendment No. 4 to the Foreclosure Sale Agreement will be executed shortly, further extending the milestone deadlines. Failure to execute Amendment No. 4 to the Foreclosure Sale agreement could result in the failure to achieve any of the milestones required under the Agreement, which in turn could result in milestone payments totaling $4.3 million to become immediately due and payable. However, Xenogenics has not accrued the $4.3 million commitment because it fully expects that Amendment No. 4 will be executed in the very near future, or if not, that it would be able to rely on the Financial Hardship exemption in the Foreclosure Sale Agreement to protect it from the required payment of $4.3 million.

ORGANIZATION_AND_NATURE_OF_OPE1

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)	9 Months Ended
	Aug. 31, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements and related notes of MultiCell and its subsidiaries have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial statements. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for a fair presentation have been included. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2013, previously filed with the SEC. The results of operations for the three-month and nine-month periods ended August 31, 2014, are not necessarily indicative of the operating results for the fiscal year ending November 30, 2014. The condensed consolidated balance sheet as of November 30, 2013, has been derived from the Company’s audited consolidated financial statements.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	RECENT ACCOUNTING PRONOUNCEMENTS
	In August 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU 2014-15, Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern, (“ASU 2014-15”). ASU 2014-15 requires management to perform interim and annual assessments on whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year of the date the financial statements are issued and to provide related disclosures, if required. ASU 2014-15 will be effective for the Company’s fiscal year beginning December 1, 2016 and subsequent interim periods. Management is currently evaluating the impact of the pending adoption of ASU 2014-15 on the Company’s consolidated financial statements.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 will be effective for the Company retrospectively beginning December 1, 2017, with early adoption not permitted. Management is currently evaluating the impact of the pending adoption of ASU 2014-09 on the Company’s consolidated financial statements.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”) to provide guidance on the presentation of unrecognized tax benefits. ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. ASU 2013-11 is effective January 1, 2015, with earlier adoption permitted. ASU 2013-11 should be applied prospectively with retroactive application permitted. Management is currently evaluating the impact of the pending adoption of ASU 2013-11 on the Company’s consolidated financial statements.

SERIES_B_CONVERTIBLE_PREFERRED1

SERIES B CONVERTIBLE PREFERRED STOCK (Tables)	9 Months Ended
	Aug. 31, 2014
Series B Convertible Preferred Stock [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The fair value of the conversion feature was estimated at $33,063 ($0.0007 per share of common stock) and $18,147 ($0.0006 per share of common stock) at August 31, 2014 and November 30, 2013, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:
		August 31,			May 31,			February 28,			November 30,
		2014			2014			2014			2013
	Fair value of common stock	$	0.0007		$	0.0008		$	0.0008		$	0.0007
	Conversion price of preferred stock	$	0.0073		$	0.0078		$	0.0095		$	0.0114
	Risk free interest rate		2.35	%		2.48	%		2.66	%		2.75	%
	Expected life		10 Years			10 Years			10 Years			10 Years
	Dividend yield		-			-			-			-
	Volatility		143	%		144	%		142	%		142	%

STOCK_COMPENSATION_PLANS_Table

STOCK COMPENSATION PLANS (Tables)	9 Months Ended
	Aug. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the status of stock options granted by MultiCell at August 31, 2014, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining		Aggregate
		Under		Exercise		Contractual		Intrinsic
		Option		Price		Life		Value
	Outstanding at November 30, 2013		50,399,503	$	0.004		3.7 years	$	-
	Granted		25,074,710		0.0008
	Exercised		-		-
	Expired or forfeited		-4,030,000		0.011
	Outstanding at August 31, 2014		71,444,213	$	0.0025		3.6 years	$	-
	Exercisable at August 31, 2014		54,300,697	$	0.003		3.4 years	$	-
Xenogenics Corporation [Member]	'
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the status of Xenogenics’ stock options at August 31, 2014, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining
		Under		Exercise		Contractual
		Option		Price		Life
	Outstanding at November 30, 2013		4,250,000	$	0.246		2.3 years
	Granted		-	$	-
	Exercised		-	$	-
	Expired or forfeited		-3,000,000	$	0.246
	Outstanding at August 31, 2014		1,250,000	$	0.246		2.4 years
	Exercisable at August 31, 2014		1,250,000	$	0.246		2.4 years

STOCK_WARRANTS_Tables

STOCK WARRANTS (Tables)	9 Months Ended
	Aug. 31, 2014
Warrants and Rights Note Disclosure [Abstract]	'
Schedule of Share-based Compensation Award, Shares Under Warrants [Table Text Block]	'
	A summary of the status of warrants at August 31, 2014, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining	Aggregate
		Under		Exercise		Contractual	Intrinsic
		Warrants		Price		Life	Value
	Outstanding at November 30, 2013		7,829,030	$	0.72	1.5 years	$	-
	Issued		-	$	-
	Exercised		-747,000	$	1.09
	Expired		-134,000	$	0.5
	Outstanding at August 31, 2014		6,948,030	$	0.68	2.0 years	$	-

NET_INCOME_LOSS_PER_COMMON_SHA1

NET INCOME (LOSS) PER COMMON SHARE (Tables)	9 Months Ended
	Aug. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table sets forth the computation of basic and diluted income (loss) per common share for the periods indicated:
		For the Three Months Ended				For the Nine Months Ended
		August 31,				August 31,
		2014		2013		2014			2013
	Numerator:
	Net income (loss)	$	225,029	$	-303,096	$	-376,734		$	-903,578
	Interest on convertible debentures		451		-		-			-
	Numerator for diluted income (loss) per common share	$	225,480	$	-303,096	$	-376,734		$	-903,578
	Denominator:
	Weighted-average shares of common stock - basic		3,971,690,410		2,105,332,608		3,519,485,044			1,730,465,999
	Dilutive effect of:
	Conversion of Series B converible preferred stock		44,205,128		-		-			-
	Conversion of convertible debentures and exercise of LJCI warrants		1,056,441,230		-		-			-
	Weighted-average shares of common stock - diluted		5,072,336,768		2,105,332,608		3,519,485,044			1,730,465,999
	Net income (loss) per common share - basic	$	0	$	0	$	0		$	0
	Net income (loss) per common share - diluted	$	0	$	0	$	0		$	0
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	Common stock equivalents excluded from income (loss) per common share calculations because their effect would have been anti-dilutive are as follows:
		For the Three Months Ended				For the Nine Months Ended
		August 31,				August 31,
		2014		2013		2014		2013
	Warrants		3,180,401		7,974,030	6,948,030			7,974,030
	Stock options		71,444,213		50,399,503	71,444,213			50,399,503
	Series B convertible preferred stock		-		27,806,452	47,232,877			27,806,452
	Convertible debenture		-		5,819,876,621	8,630,382,163			5,819,876,621
			74,624,614		5,906,056,606	8,756,007,283			5,906,056,606

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Aug. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
	Liabilities measured at fair value on a recurring basis at August 31, 2014 and November 30, 2013, are summarized as follows:
		August 31, 2014								November 30, 2013
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Derivative liability	$	-	$	33,063	$	-	$	33,063	$	-	$	18,147	$	-	$	18,147

ORGANIZATION_AND_NATURE_OF_OPE2

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details Textual) (USD $)	9 Months Ended
	Aug. 31, 2014	Aug. 15, 2014
Xenogenics Corporation [Member]	'	'
Accounting Policies [Line Items]	'	'
Noncontrolling Interest, Ownership Percentage by Parent	95.30%	'
Multicell Immunotherapeutics [Member]	'	'
Accounting Policies [Line Items]	'	'
Noncontrolling Interest, Ownership Percentage by Parent	85.10%	67.00%
Conversion of Inter Company Liabilities into Common Stock	$1,165,867	'

GOING_CONCERN_Details_Textual

GOING CONCERN (Details Textual) (USD $)	Aug. 31, 2014	Nov. 30, 2013	Aug. 31, 2014	Nov. 30, 2007
			La Jolla Cove Investors [Member]	La Jolla Cove Investors [Member]
Going Concern [Line Items]	'	'	'	'
Accumulated Deficit	$43,865,945	$43,489,211	'	'
Investment Warrants, Exercise Price	'	'	$1.09	$1.09
Shares Remaining under Stock Warrant	'	'	3,767,629	'
Convertible Debt	'	45,146	37,676	'
Potential Proceeds from Warrant Exercises	'	'	$4,100,000	'
Debt Instrument, Convertible Percentage of Equity Instruments, Maximum	'	'	9.99%	'
Investment Warrants Expiration Date	'	'	28-Feb-16	'

PAYABLE_TO_RELATED_PARTY_Detai

PAYABLE TO RELATED PARTY (Details Textual) (USD $)	Aug. 31, 2014	Nov. 30, 2013	Sep. 30, 2005
Related Party Transaction [Line Items]	'	'	'
Due To Related Parties, Current	$50,000	$50,000	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	'	'	$200,000

CONVERTIBLE_DEBENTURES_Details

CONVERTIBLE DEBENTURES (Details Textual) (USD $)

9 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

Aug. 31, 2014

Aug. 31, 2013

Nov. 30, 2013

Aug. 31, 2014

Aug. 31, 2013

Aug. 31, 2014

Aug. 31, 2013

Feb. 20, 2014

Aug. 16, 2011

Aug. 31, 2014

Aug. 31, 2013

Nov. 30, 2007

Warrant [Member]

Warrant [Member]

Common Stock [Member]

Common Stock [Member]

La Jolla Cove Investors [Member]

La Jolla Cove Investors [Member]

La Jolla Cove Investors [Member]

La Jolla Cove Investors [Member]

La Jolla Cove Investors [Member]

Convertible Debentures [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Securities Purchase, Agreement Date

'

'

'

'

'

'

'

'

'

'

'

28-Feb-07

Proceeds from Convertible Debenture, Principal Amount

'

'

'

'

'

'

'

'

'

'

'

$100,000

Debt Conversion, Original Debt, Due Date of Debt

'

'

'

'

'

'

'

'

'

'

'

28-Feb-12

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

28-Feb-16

28-Feb-14

'

'

'

Debt Conversion, Original Debt, Interest Rate of Debt

4.75%

4.75%

'

'

'

'

'

'

'

'

'

'

Warrants Issued Number

'

'

'

'

'

'

'

'

'

'

'

10,000,000

Class of Warrant, Exercisable Period

'

'

'

'

'

'

'

'

'

'

'

'5 years

Exercise of Warrant upon Conversion of Debt

'

'

'

'

'

'

'

'

'

'each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share

'

'

Maximum Conversion Limit of Debt

'

'

'

'

'

'

'

'

'

'The Conversion Price is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert.

'

'

Debentures Converted, Value

7,470

9,430

'

'

'

15,956,003

10,404,936

'

'

7,470

9,430

'

Debentures Converted, Shares

'

'

'

'

'

1,595,600,327

1,040,493,584

'

'

'

'

'

Potential Issuable Shares Under Convertible Debenture

8,600,000,000

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Exercise of Warrants

'

'

'

747,000

943,000

747,000

943,000

'

'

'

'

'

Number of Warrants, Remaining Unexercised

'

'

'

'

'

'

'

'

'

3,767,629

'

'

Investment Warrants, Exercise Price

'

'

'

'

'

'

'

'

'

$1.09

'

$1.09

Equity Method Investment, Ownership Percentage

'

'

'

'

'

'

'

'

'

9.99%

'

'

Proceeds from Warrant Exercises

814,230

1,027,870

'

814,230

1,027,870

'

'

'

'

'

'

'

Advance from warrant holder

22,400

'

61,950

'

'

'

'

'

'

'

'

'

Convertible Debt

'

'

$45,146

'

'

'

'

'

'

$37,676

'

'

LICENSE_AGREEMENTS_AND_DEFERRE1

LICENSE AGREEMENTS AND DEFERRED REVENUE (Details Textual) (USD $)

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Aug. 31, 2014

9-May-14

Sep. 30, 2010

Aug. 31, 2014

Aug. 31, 2013

Aug. 31, 2014

Aug. 31, 2013

Nov. 30, 2013

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2013

Aug. 31, 2014

Aug. 31, 2013

Nov. 30, 2013

Rutgers License Agreement [Member]

Rutgers License Agreement [Member]

Corning Incorporated [Member]

Corning Incorporated [Member]

Corning Incorporated [Member]

Corning Incorporated [Member]

Corning Incorporated [Member]

Corning Incorporated [Member]

Corning Incorporated [Member]

Pfizer Incorporated [Member]

Pfizer Incorporated [Member]

Pfizer Incorporated [Member]

Pfizer Incorporated [Member]

Pfizer Incorporated [Member]

Xenogenics [Member]

Execution Of Licence Agreement [Member]

Completion Of Licence Agreement [Member]

Deferred Revenue Arrangement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License and Maintenance Revenue

'

'

'

'

'

'

'

'

$375,000

$375,000

'

'

'

'

'

Deferred Revenue, Revenue Recognized

'

'

'

11,029

33,088

11,029

33,088

'

'

'

1,300

3,900

1,300

3,900

'

Deferred Revenue

'

'

'

444,853

'

444,853

'

477,942

'

'

16,900

'

16,900

'

20,800

Deferred Revenue, Amortization Period

'

'

'

'

'

'2024-10

'

'

'

'

'

'

'2018-01

'

'

License And Purchase Agreement Description

'The Company has an exclusive license and purchase agreement (the Agreement) with Corning Incorporated (Corning) of Corning, New York.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License Costs

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

License Maintenance Fee For Third Anniversary

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

License Maintenance Fee For Fourth Anniversary

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

License Agreement, Unpaid Costs

'

'

136,000

'

'

'

'

'

'

'

'

'

'

'

'

Unpaid License Fees

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Unpaid Patent Costs

'

75,665

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Interest

'

$8,375

'

'

'

'

'

'

'

'

'

'

'

'

'

SERIES_B_CONVERTIBLE_PREFERRED2

SERIES B CONVERTIBLE PREFERRED STOCK (Details) (Series B Convertible Preferred Stock [Member], USD $)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2014	31-May-14	Aug. 31, 2014	Nov. 30, 2013
Series B Convertible Preferred Stock [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value of common stock	$0.00	$0.00	$0.00	$0.00
Conversion price of preferred stock	$0.01	$0.01	$0.01	$0.01
Risk free interest rate	2.66%	2.48%	2.35%	2.75%
Expected life	'10 years	'10 years	'10 years	'10 years
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	142.00%	144.00%	143.00%	142.00%

SERIES_B_CONVERTIBLE_PREFERRED3

SERIES B CONVERTIBLE PREFERRED STOCK (Details Textual) (USD $)	9 Months Ended	12 Months Ended
	Aug. 31, 2014	Nov. 30, 2013
Series B Redeemable Convertible Stock [Line Items]	'	'
Preferred Stock, Shares Authorized	963,000	963,000
Preferred Stock, Original Conversion Price	$0.32	'
Preferred Stock, Dividend Payment Rate	'Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum.	'
Dividends Payable	$290,724	$290,724
Fair Value of Embedded Conversion Feature, per share	$0.00	$0.00
Preferred Stock, Shares Outstanding	0	0
Derivative Liability	33,063	18,147
Board of Directors Chairman [Member]	'	'
Series B Redeemable Convertible Stock [Line Items]	'	'
Preferred Stock, Shares Authorized	1,000,000	'
Series B Convertible Preferred Stock [Member]	'	'
Series B Redeemable Convertible Stock [Line Items]	'	'
Preferred Stock, Shares Authorized	17,000	17,000
Preferred Stock, Purchase Price, Per Share, Value	$100	'
Reduced Conversion Price Percentage	85.00%	'
Preferred Stock Reduced Conversion Price	$0.01	$0.01
Dividends Payable Included in Permanent Equity	125,516	125,516
Dividends Payable, Included in Accounts Payable and Accrued Expenses	$165,208	$165,208
Preferred Stock, Shares Outstanding	3,448	3,448
Common Class [Member]	'	'
Series B Redeemable Convertible Stock [Line Items]	'	'
Convertible Preferred Stock, Shares Issuable upon Conversion	47,232,877	30,245,614

SERIES_I_CONVERTIBLE_PREFERRED1

SERIES I CONVERTIBLE PREFERRED STOCK (Details Textual)	Aug. 31, 2014	Nov. 30, 2013	Jul. 13, 2004	Aug. 31, 2014	Nov. 30, 2013	Aug. 31, 2014
			Accredited Investors [Member]	Series I Convertible Preferred Stock [Member]	Series I Convertible Preferred Stock [Member]	Board of Directors Chairman [Member]
Series I Redeemable Convertible Stock [Line Items]	'	'	'	'	'	'
Preferred Stock, Shares Authorized	963,000	963,000	'	20,000	20,000	1,000,000
Preferred Stock, Shares Issued	0	0	20,000	0	0	'

STOCK_COMPENSATION_PLANS_Detai

STOCK COMPENSATION PLANS (Details) (USD $)	1 Months Ended	9 Months Ended	12 Months Ended	1 Months Ended	9 Months Ended	12 Months Ended
	Aug. 16, 2013	Aug. 31, 2014	Nov. 30, 2013	Nov. 30, 2010	Aug. 31, 2014	Nov. 30, 2013
				Xenogenics Corporation [Member]	Xenogenics Corporation [Member]	Xenogenics Corporation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Shares Under Option, Outstanding, Beginning balance	'	50,399,503	'	'	4,250,000	'
Shares Under option, Granted	5,000,000	25,074,710	'	2,500,000	0	'
Shares Under Option, Exercised	'	0	'	'	0	'
Shares Under option, Expired or forfeited	'	-4,030,000	'	'	-3,000,000	'
Shares Under Option,Outstanding, Ending balance	'	71,444,213	50,399,503	'	1,250,000	4,250,000
Shares Under Option,Exercisable	'	54,300,697	'	'	1,250,000	'
Weighted Average Exercise Price, Outstanding, Beginning balance	'	$0.00	'	'	$0.25	'
Weighted Average Exercise Price, Granted (in dollars per share)	$0.00	$0.00	'	$0.25	$0	'
Weighted Average Exercise Price, Exercised (in dollars per share)	'	$0	'	'	$0	'
Weighted Average Exercise Price, Expired or forfeited (in dollars per share)	'	$0.01	'	'	$0.25	'
Weighted Average Exercise Price, Outstanding, Ending balance	'	$0.00	$0.00	'	$0.25	$0.25
Weighted Average Exercise price, Exercisable (in dollars per share)	'	$0.00	'	'	$0.25	'
Weighted Average Remaining Contractual Life, Outstanding	'	'3 years 7 months 6 days	'3 years 8 months 12 days	'	'2 years 4 months 24 days	'2 years 3 months 18 days
Weighted Average Remaining Contractual Life, Exercisable	'	'3 years 4 months 24 days	'	'	'2 years 4 months 24 days	'
Aggregate Intrinsic Value, Outstanding, Beginning balance	'	$0	'	'	'	'
Aggregate Intrinsic Value, Outstanding, Ending balance	'	0	0	'	'	'
Aggregate Intrinsic Value, Exercisable	'	$0	'	'	'	'

STOCK_COMPENSATION_PLANS_Detai1

STOCK COMPENSATION PLANS (Details Textual) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Jan. 15, 2014

Aug. 16, 2013

Aug. 31, 2014

Aug. 31, 2013

Aug. 31, 2014

Aug. 31, 2013

Nov. 30, 2010

Aug. 31, 2013

Aug. 31, 2014

Aug. 31, 2013

Feb. 03, 2011

Oct. 31, 2010

Jan. 15, 2014

Aug. 16, 2013

Aug. 31, 2014

Aug. 31, 2013

Jan. 15, 2014

Dec. 02, 2012

Dec. 02, 2011

Jul. 11, 2011

Xenogenics Corporation [Member]

Xenogenics Corporation [Member]

Xenogenics Corporation [Member]

Xenogenics Corporation [Member]

Xenogenics Corporation [Member]

Xenogenics Corporation [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Employee [Member]

Equity Incentive Plan 2004 [Member]

Equity Incentive Plan 2004 [Member]

Equity Incentive Plan 2004 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

8,000,000

5,000,000

'

'

'

'

'

1,500,000

1,500,000

70,974,213

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

5,000,000

'

'

25,074,710

'

2,500,000

'

0

'

'

'

4,600,000

5,000,000

'

'

2,074,710

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

'

$0.00

'

'

$0.00

'

$0.25

'

$0

'

'

'

$0.00

$0.00

'

'

$0.00

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

$0.23

'

'

'

'

'

'

'

$0.00

$0.00

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

1.23%

'

'

'

'

'

'

'

1.68%

1.60%

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

165.00%

'

'

'

'

'

'

'

140.00%

175.00%

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'5 years

'

'

'

'

'

'5 years

'

'5 years

'5 years

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options

'

'

$12,000

'

$12,000

'

$461,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition

'1 year

'

'

'

'1 year 2 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Closing Price Share

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Original Terms of Plan

'

'

'

'

'

'

'

'

'A 10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant.

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Option, Maximum Term

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

10,806

1,893

32,741

10,705

'

51,052

'

165,161

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Unvested, Fair Value

'

'

'

'

'

'

576,250

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date

'

'

'

'

'

'

30-Nov-15

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Reversal of Stock Based Compensation Expense

'

'

'

'

'

'

'

'

-417,838

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Total

'

'

-450,194

52,945

-385,097

175,866

'

'

43,162

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation of unvested options

'

'

'

'

'

'

'

'

($461,000)

'

'

'

'

'

'

'

'

'

'

'

STOCK_WARRANTS_Details

STOCK WARRANTS (Details) (USD $)	9 Months Ended	12 Months Ended
	Aug. 31, 2014	Nov. 30, 2013
Schedule Of Stockholders Equity Note Warrants Or Rights [Line Items]	'	'
Shares Under Warrants, Outstanding , Beginning balance (in shares)	7,829,030	'
Shares Under Warrants, Issued (in shares)	0	'
Shares Under Warrants, Exercised (in shares)	-747,000	'
Shares Under Warrants, Expired (in shares)	-134,000	'
Shares Under Warrants, Outstanding, Ending balance (in shares)	6,948,030	7,829,030
Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share)	$0.72	'
Weighted Average Exercise Price, Issued (in dollars per share)	$0	'
Weighted Average Exercise price, Exercised (in dollars per share)	$1.09	'
Weighted Average Exercise Price, Expired (in dollars per share)	$0.50	'
Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share)	$0.68	$0.72
Weighted Average Remaining Contractual Life, Outstanding	'2 years	'1 year 6 months
Aggregate Intrinsic Value, Outstanding, Beginning balance	$0	'
Aggregate Intrinsic Value, Outstanding, Ending balance	$0	$0

STOCK_WARRANTS_Details_Textual

STOCK WARRANTS (Details Textual) (USD $)	1 Months Ended	9 Months Ended
	Feb. 28, 2007	Aug. 31, 2014	Aug. 31, 2013
Class of Warrant or Right [Line Items]	'	'	'
Proceeds from Warrant Exercises	'	$814,230	$1,027,870
La Jolla Cove Investors [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Proceeds from Convertible Debenture, Principal Amount	100,000	'	'
Warrants Issued Number	10,000,000	'	'
Investment Warrants, Exercise Price	$1.09	'	'
Class of Warrant, Exercisable Period	'5 years	'	'
Exercise of Warrant upon Conversion of Debt	'for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share.	'	'
Stock Issued During Period, Shares, Exercise of Warrants	'	747,000	943,000
Proceeds from Warrant Exercises	'	$814,230	$1,027,870

NET_INCOME_LOSS_PER_COMMON_SHA2

NET INCOME (LOSS) PER COMMON SHARE (Details) (USD $)	3 Months Ended		9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014	Aug. 31, 2013
Numerator:	'	'	'	'
Net income (loss)	$225,029	($303,096)	($376,734)	($903,578)
Interest on convertible debentures	451	0	0	0
Numerator for diluted income (loss) per common share	$225,480	($303,096)	($376,734)	($903,578)
Denominator:	'	'	'	'
Weighted-average shares of common stock - basic	3,971,690,410	2,105,332,608	3,519,485,044	1,730,465,999
Dilutive effect of:	'	'	'	'
Conversion of Series B converible preferred stock	44,205,128	0	0	0
Conversion of convertible debentures and exercise of LJCI warrants	1,056,441,230	0	0	0
Weighted-average shares of common stock - diluted	5,072,336,768	2,105,332,608	3,519,485,044	1,730,465,999
Net income (loss) per common share - basic (in dollars per share)	$0	$0	$0	$0
Net income (loss) per common share - diluted (in dollars per share)	$0	$0	$0	$0

NET_INCOME_LOSS_PER_COMMON_SHA3

NET INCOME (LOSS) PER COMMON SHARE (Details 1)	3 Months Ended		9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014	Aug. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	74,624,614	5,906,056,606	8,756,007,283	5,906,056,606
Series B convertible preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	27,806,452	47,232,877	27,806,452
Convertible debenture [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	5,819,876,621	8,630,382,163	5,819,876,621
Warrant [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,180,401	7,974,030	6,948,030	7,974,030
Stock Option [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	71,444,213	50,399,503	71,444,213	50,399,503

NET_INCOME_LOSS_PER_COMMON_SHA4

NET INCOME (LOSS) PER COMMON SHARE (Details Textual) (USD $)	Aug. 31, 2014	Nov. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Convertible Debentures	$0	$45,146
La Jolla Cove Investors [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Convertible Debentures	$37,676	'
Number of Warrants, Remaining Unexercised	3,767,629	'
Equity Method Investment, Ownership Percentage	9.99%	'

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Aug. 31, 2014	Nov. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	$33,063	$18,147
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	33,063	18,147
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	$0	$0

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	9 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Subsequent Event [Line Items]	'	'
Proceeds from Warrant Exercises	$814,230	$1,027,870
Subsequent Event [Member]	'	'
Subsequent Event [Line Items]	'	'
Debt Conversion, Original Debt, Amount	500	'
Debt Conversion, Converted Instrument, Shares Issued	122,172,222	'
Stock Issued During Period, Shares, Exercise Of Warrants	50,000	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.09	'
Proceeds from Warrant Exercises	54,500	'
Subsequent Event [Member] | Amendment No 3 [Member]	'	'
Subsequent Event [Line Items]	'	'
Total Milestones Payments Due	4,300,000	'
Subsequent Event [Member] | Amendment No 4 [Member]	'	'
Subsequent Event [Line Items]	'	'
Total Milestones Payments Due	$4,300,000	'